AzTrials
AzTrials

Parkinson DiseaseNCT05820425

Local Fields Potentientals of the Subthalamic Nucleus in Patients With Parkinson's Disease

An observational study of Parkinson Disease, run by University Hospital, Grenoble at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Neuropsychiatric fluctuations are frequent and debilitating non-motor disorders in Parkinson's disease. Subthalamic stimulation is an effective treatment for motor and non-motor neuropsychiatric fluctuations in Parkinson's disease, which has also allowed to better characterize the electrophysiological activity of the… Read more about this study

Who is it for?
Ages 30 to 75 years
Conditions the study is for
Parkinson Disease
What is being tested?
LFP and EEG recording
How many people
12 participants
Where
1 siteFrance
Study dates
7 Apr 2023to Feb 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: PD patients with motor and non motor fluctuations, operated within the last 10 days for STN stimulation (PERCEPT implant)

Who may be able to join

  • Age between 30 and 75 years
  • Diagnosis of Parkinson's disease with fluctuations and/or dyskinesias
  • Ability to collaborate and fill a questionnaire in the OFF state condition (this criterion will be assessed based on the results of the preoperative screening to retain indication for STN stimulation, which takes place whenever a PD patient has to undergo DBS surgery)
  • Surgery for bilateral STN stimulation with a Percept® (Medtronic) in the last 10 days
  • Absence of dementia (defined as MoCA score > 24)

Who cannot join

  • Active psychosis
  • Patients unable to provide an informed consent or under gardianship
  • Patients under judicial supervision or deprived of liberty
  • Pregnancy and breastfeeding

Trial locations and contacts

1 site in 1 country.

France1 site, 1 recruiting
  • CHU Grenoble Alpes

    Grenoble, 38043

    Anna Castrioto, +33476769452, acastrioto@chu-grenoble.fr

    Pierre PELISSIER, +33476769459, ppelissier@chu-grenoble.fr

    Recruiting

Other trials in France

About this study

Official title: Local Fields Potentials of the Subthalamic Nucleus in Patients With Parkinson's Disease and Neuropsychiatric Fluctuations

Neuropsychiatric fluctuations are frequent and debilitating non-motor disorders in Parkinson's disease. Subthalamic stimulation is an effective treatment for motor and non-motor neuropsychiatric fluctuations in Parkinson's disease, which has also allowed to better characterize the electrophysiological activity of the subthalamic nucleus in patients with Parkinson's disease. Numerous studies have been carried out on electrophysiological activity correlated with motor disorders, showing that akinesia is correlated with an abnormal synchronization in the beta frequency band (13-30Hz) in the dorsal motor part of the subnucleus. thalamic. This abnormal synchronization is reduced when the akinesia improves with dopaminergic treatment. On the cognitive-behavioural non-motor side, electrophysiological studies are less numerous, but suggest an involvement of the subthalamic nucleus (with an abnormal synchronization in the lower frequency bands). Currently, the electrophysiological correlates of neuropsychiatric fluctuations are unknown. In addition, all studies on electrophysiological activity are carried out immediately after the intervention, and before the implantation of the pacemaker. It is unknown whether the electrophysiological correlates of motor and non-motor fluctuations change following their transient improvement observed in the setting of chronic stimulation of the subthalamic nucleus and chronic reduction of dopaminergic treatment. The new PERCEPT stimulators (Medtronic) available on the market make it possible to record long-term electrophysiological activity for the first time. With this study we want to define the electrophysiological markers of neuropsychiatric fluctuations and their change over time.

Read the detailed description

In PD several studies have shown an abnormal synchronized activity in the beta band (13-30 Hz) in the motor dorsal STN, which correlates with bradykinesia. This abnormal activity is decreased by dopaminergic treatment and movement. In contrast, higher alpha activity is concentrated in the ventromedial part of the nucleus. Anatomically, it has been shown that the motor dorsal subthalamic nucleus is connected with the motor frontal cortex, whereas its non-motor ventral part is connected to the premotor and the prefrontal cortex.

More recently, an increasing attention has been focused on the key role of the STN in emotion and cognition in Parkinson's disease. Neuropsychiatric symptoms indeed represent a real burden for patients with PD and their caregivers. Patients might experience fatigue, depressive symptoms, anxiety, apathy, impulse control disorders, punding, hallucinations, and impaired cognition. Moreover, neuropsychiatric symptoms might fluctuate along the day. During the off state, patients might present with fatigue, lack of energy and motivation, low mood and slowness of thought, whereas during the on state they experience a sensation of well-being, high motivation, logorrhoea with easy flow of ideas, and good attention span and liveliness. Little is known about the electrophysiological correlates of such neuropsychiatric symptoms. An increase in the background activity and a reduced oscillatory activity in the alpha spectrum was observed in the ventral part of the right STN after vocal emotional stimuli. A change in the oscillatory activity in the alpha spectrum of the STN has been recorded after visual emotional stimuli. A theta activity in the ventral region of the STN has been recorded in PD patients with impulse control disorders while on medication.

Recently, a new tool, the neuropsychiatric fluctuations scale, has been developed. This scale, contrary to the other scales measuring the non-motor fluctuations, which are mainly retrospective, allows to measure the neuropsychiatric state of the patient at the very moment of the test. This is a critical advantage as patients can be anosognosic of their fluctuations. The neuropsychiatric fluctuations scale allows measuring the neuropsychiatric state of the patient "in real time", just as the MDS UPDRS assesses the motor condition.

At present, the electrophysiological marker of neuropsychiatric fluctuations in PD is unknown. Moreover, all electrophysiological data on STN activity comes from the postoperative phase and no data are available on their evolution over time.

The PERCEPT (Medtronic) allows to record STN activity not only in the immediate postoperative phase, but also in the medium and long-term follow-up, providing an excellent tool to investigate the electrophysiological activity of the subthalamic nucleus, and its changes over time.

In addition, while there are studies on the electrophysiological correlates of motor activity in PD, no studies are available on the change of this activity in the same patient after long follow-up. It is unknown whether the electrophysiological markers of motor and neuropsychiatric fluctuations change over time, together with the improvement of fluctuations induced by chronic stimulation and reduction of dopaminergic medication. From a clinical point of view, a motor and neuropsychiatric desensitization to levodopa has been shown in PD patients treated with chronic STN stimulation. Although relatively unknown and understudied, levodopa desensitization carries significant consequence in PD, such as malignant stimulation withdrawal syndrome. To determine how the electrophysiological markers of the OFF and the ON states change over time in the same patient not only will help to elucidate the mechanisms underlying this desensitization, but it will be also crucial for implementing algorithms for adaptive stimulation.

The purpose of our study is to record the STN activity in PD patients treated with STN stimulation during neuropsychiatric and motor fluctuations and their changes over time.

RESEARCH HYPOTHESIS AND EXPECTED RESULTS Our hypothesis is that neuropsychiatric fluctuations are associated with a change in the low-frequencies band activity in the ventral region of the STN, and that motor fluctuations are associated with changes in the beta band activity in the dorsal motor region of the STN. We expect a reduction of these abnormal activities over time, associated with the reduction of fluctuations.

Great efforts are to date made in order to create an adaptive stimulation, characterized by a real-time adaptation of parameters of stimulation to the fluctuations of the patient state. Adaptive stimulation would be more efficient than the current continuous stimulation system. Results of this study will allow to better understanding the pathophysiological basis of neuropsychiatric and motor fluctuation, and moreover to implement algorithms for create an adaptive stimulation.

Being tested
LFP and EEG recording
Keywords
Local Field Potentials, Neuropsychiatric Fluctuations Scale, Subthalamic nucleus stimulation
Medical subject headings
Parkinson Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LFP and EEG recordingOther

    STN LFP and EEG recording during the OFF and ON medication condition

Study groups in NCT05820425
Study groupRoleWhat they receive
Patients with Parkinson's disease with fluctuations and/or dyskinesias treated by STN DBSPatients with Parkinson's disease with fluctuations and/or dyskinesias treated by STN DBS, using PERCEPT device (Medtronic)
Receives: Other: LFP and EEG recording

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The LFPs recordings from the STN correlating with the neuropsychiatric OFF and ON

    Correlation will be performed within a general mixed effect model approach. The dependent variable will be the power spectral density (PSD, expressed as logpower (µV^2)) of the subthalamic nucleus local field potentials estimated with the Welch method. The independant variable will be measured using the neuropsychiatric fluctuations scale score.

    Measured: in the 10 days following surgery

  2. The LFPs recordings from the STN correlating with the neuropsychiatric OFF and ON

    Correlation will be performed within a general mixed effect model approach. The dependent variable will be the power spectral density (PSD, expressed as logpower (µV^2)) of the subthalamic nucleus local field potentials estimated with the Welch method. The independant variable will be measured using the neuropsychiatric fluctuations scale score.

    Measured: at 3 months after surgery

  3. The LFPs recordings from the STN correlating with the neuropsychiatric OFF and ON

    Correlation will be performed within a general mixed effect model approach. The dependent variable will be the power spectral density (PSD, expressed as logpower (µV^2)) of the subthalamic nucleus local field potentials estimated with the Welch method. The independant variable will be measured using the neuropsychiatric fluctuations scale score.

    Measured: at 1 year after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Apr 2023
  2. Study start7 Apr 2023
  3. Primary completionFeb 2025 (estimated)
  4. Study completionFeb 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
12 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05820425
Sponsor's protocol ID
38RC21.0394
Other IDs
2022-A00004-39
Status last verified
May 2024
First submitted
6 Mar 2023
Last updated
3 Jun 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Parkinson Disease, run by University Hospital, Grenoble at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 3 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Pierre Pelissier, MsC (4 76 76 94 59 ext. +33, ppelissier@chu-grenoble.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The LFPs recordings from the STN correlating with the neuropsychiatric OFF and ON (time frame: in the 10 days following surgery). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jun 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in